<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20140224016705N11</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-11-05</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Evaluating the effects of local endometrial injury on success of pregnancy rate in patients candidate for in vitro fertilization.</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the effects of local endometrial injury on success of pregnancy rate in patients candidate for in vitro fertilization (IVF).</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>324</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58590</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Infertility.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Includes infertile women with at least one failed IVF history and re-candidate for IVF referred to the Reproductive Clinic of Mahdieh Hospital in Tehran, whose endometrial thickness is based on inappropriate ultrasound criteria (echogenic or thin view with a thickness of less than 5 mm) and in ultrasound or hysteroscopy of internal pathology They will not have a uterus such as a myoma or fibroid. Patients are routinely involved in the IVF process and ovulation and in vitro fertilization will be performed for each patient. The initial ultrasound will be done before the intervention in the luteal phase (about a week before the next period). Then, on the first to third day of the cycle, small blows were applied to different parts of the uterus using a pipette and small scratches were created. On day 8-10 of the cycle, ultrasound was performed again and the condition of the endometrium was examined. If there is a triple line view or a thickness of more than 7 mm, while starting progesterone as a cyclogest suppository, the patient is introduced for embryo transfer to be done in two or three days. Β-hCG titers were also checked 2 weeks after embryo transfer. Also, 5 weeks after the transfer, the presence of clinical pregnancy (formation of pregnancy sac and fetal heart) will be examined by transvaginal ultrasound. Outcomes studied include the effect of endometrial abrasion on endometrial condition adaptation, β-hCG positivity (greater than 10 mIU / mL) and the presence of clinical pregnancy with ultrasound. Intervention 2: Control group: Each patient is considered as a control group. In this way, each patient is classified as a control group according to the infertility conditions in terms of uterine endometrial diameter before the intervention. Conditions before and after endometrial ablation with papillae in terms of uterine diameter and fertility will be evaluated as case and control groups.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is According to the results, local application is considered regionally</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>zahra heidar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mahdieh hospital,Fadaeean Eslam street,Shoosh square</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1185817311</zip>
        <telephone>+98 21 5506 2628</telephone>
        <email>dr_zheidar@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>zahra heidar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mahdieh hospital,Fadaeean Eslam street,Shoosh square</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1185817311</zip>
        <telephone>+98 21 5506 2628</telephone>
        <email>dr_zheidar@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>History of infertility with a history of unsuccessful IVF
candidate for in vitro fertilization
Existence of inappropriate endometrial thickness based on ultrasound
Age 40 years or less
Do not use OCP or GnRH for FET in the previous cycle
Appropriate quality of embryos for transfer</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Vaginal or cervical active infection
Endometrial Hyperplasia
Existence of endometritis
Presence of known intrauterine pathologies on ultrasound or hysteroscopy such as fibroids or myomas
Asherman syndrome
Uterine anomaly</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N97</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Female infertility</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Includes infertile women with at least one failed IVF history and re-candidate for IVF referred to the Reproductive Clinic of Mahdieh Hospital in Tehran, whose endometrial thickness is based on inappropriate ultrasound criteria (echogenic or thin view with a thickness of less than 5 mm) and in ultrasound or hysteroscopy of internal pathology They will not have a uterus such as a myoma or fibroid. Patients are routinely involved in the IVF process and ovulation and in vitro fertilization will be performed for each patient. The initial ultrasound will be done before the intervention in the luteal phase (about a week before the next period). Then, on the first to third day of the cycle, small blows were applied to different parts of the uterus using a pipette and small scratches were created. On day 8-10 of the cycle, ultrasound was performed again and the condition of the endometrium was examined. If there is a triple line view or a thickness of more than 7 mm, while starting progesterone as a cyclogest suppository, the patient is introduced for embryo transfer to be done in two or three days. Β-hCG titers were also checked 2 weeks after embryo transfer. Also, 5 weeks after the transfer, the presence of clinical pregnancy (formation of pregnancy sac and fetal heart) will be examined by transvaginal ultrasound. Outcomes studied include the effect of endometrial abrasion on endometrial condition adaptation, β-hCG positivity (greater than 10 mIU / mL) and the presence of clinical pregnancy with ultrasound.</i_keyword>
      <i_keyword>Control group: Each patient is considered as a control group. In this way, each patient is classified as a control group according to the infertility conditions in terms of uterine endometrial diameter before the intervention. Conditions before and after endometrial ablation with papillae in terms of uterine diameter and fertility will be evaluated as case and control groups.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Existence of clinical pregnancy (formation of pregnancy sac and fetal heart) in IVF patient under the intervention of endometrial abrasion with papillae. Timepoint: 5 weeks after the transfer, transvaginal ultrasound will examine the presence of clinical pregnancy (formation of pregnancy sac and fetal heart). Method of measurement: transvaginal ultrasound.</prim_outcome>
      <prim_outcome>β-hCG positivity (greater than 10 mIU / mL). Timepoint: Β-hCG titer was checked 2 weeks after embryo transfer. Method of measurement: Using a laboratory-approved β-hCG test.</prim_outcome>
      <prim_outcome>The effect of endometrial abrasion on endometrial condition. Timepoint: On day 8-10 of the cycle, an ultrasound will be performed again and the condition of the endometrium will be examined. Method of measurement: transvaginal ultrasound.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-01-31</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Shahid Beheshti university of medical sciences, Arabi Ave, Yamen St, Chamran Highway, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
